Source comparison
GHRP-2 Acetate vs MK-677: Research Applications Comparison
Administration Route Subcutaneous injection, 2–3× daily Oral capsule/suspension, 1× daily MK-677 eliminates injection logistics. Critical for extended protocols or remote research sites Half-Life 20–30 minutes (GH pulse duration: 3–4 hours) Approximately 24 ho
This comparison does not assign a generated winner or score.
- Administration Route
- Subcutaneous injection, 2–3× daily
- Oral capsule/suspension, 1× daily
- MK-677 eliminates injection logistics. Critical for extended protocols or remote research sites
- Half-Life
- 20–30 minutes (GH pulse duration: 3–4 hours)
- Approximately 24 hours
- GHRP-2 mimics physiological pulsatility; MK-677 sustains steady-state elevation
- GH Release Pattern
- Sharp pulses peaking at 15–20 ng/mL within 30 min
- Sustained elevation of mean 24-hour GH by 60–97%
- Pulsatile (GHRP-2) aligns with circadian models; sustained (MK-677) suits anabolic consistency studies
- IGF-1 Elevation
- Moderate, dose-dependent, returns to baseline between doses
- Sustained 40–60% increase maintained across 24 hours
- MK-677 produces more stable IGF-1 levels. Relevant for tissue-building endpoint measurements
- Receptor Desensitisation Risk
- Low when dosed 2–3× daily with 4–6 hour intervals
- Minimal. No documented tachyphylaxis in 12-month studies
- Both maintain efficacy across extended cycles; neither requires cycling off to preserve response
- Storage & Stability
- Requires refrigeration (2–8°C) post-reconstitution; 28-day shelf life
- Stable at room temperature as powder; 12–24 months shelf life
- MK-677 drastically simplifies storage and shipping logistics for multi-site research
- GHRP-2 is preferred when research objectives require observing GH pulsatility effects. Circadian rhythm studies, sleep architecture analysis, or protocols measuring acute metabolic shifts in response to sharp GH peaks. MK-677 suits body composition studies, bone density research, and extended metabolic investigations where sustained anabolic signalling is the endpoint. Combining both compounds in the same protocol is redundant. They act on the same receptor pathway and do not produce additive GH elevation.